A generic version of multiple sclerosis drug Copaxone was introduced in 2015, but it has done little to lower drug costs for MS patients, NPR reported. Yearly costs for MS drugs can run as high as $50 ...

Shares of Teva Pharmaceutical Industries Ltd. climbed Monday in the first trading day after a federal court reaffirmed patents protecting the drugmaker's biggest brand-name product, the multiple ...

WASHINGTON — Teva Pharmaceutical on Wednesday was denied in its suit to block approval of Mylan's and Sandoz' generic Copaxone, a multiple sclerosis drug, 10 days before the patent on the medication ...

FILE - Israeli flag flies outside Teva Pharmaceutical facility building in Neot Hovav, Israel, on Dec. 14, 2017. (AP Photo/Tsafrir Abayov, File) BRUSSELS (AP) — The European Commission said Thursday ...

BOSTON — A new generic version of glatiramer acetate for multiple sclerosis (MS) has shown similar results to the branded agent (Copaxone, Teva Pharmaceuticals) in terms of reduction in lesions on ...

The European Commission (EC) has fined pharmaceutical company Teva €462.6 million for “systematically spread[ing] misleading information” and abusing its dominant position to delay competition to its ...

Copaxone and its generic form, Glatopa, may lead to anaphylaxis even in patients who’ve been taking the medication for months without incident. The FDA warns that the injectable MS drugs Copaxone and ...

Mylan on Tuesday earned Food and Drug Administration approval for its generic version of Teva’s multiple sclerosis drug Copaxone. 1. Mylan’s glatiramer acetate injection is intended to treat patients ...